{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T02:50:33Z","timestamp":1784947833704,"version":"3.55.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T00:00:00Z","timestamp":1685318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T00:00:00Z","timestamp":1685318400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We compared outcomes of adult patients with secondary acute myeloid leukemia (sAML) versus de novo AML after non-T-depleted haploidentical stem cell transplant (HaploSCT) with post-transplant cyclophosphamide (PTCy). Seventeen hundred and eleven AML patients (sAML-231, de novo-1480) in first complete remission transplanted from 2010 to 2021, were included. Patients with de novo AML were younger, median age 55.8 versus 60.8\u00a0years, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001, had better transplantation comorbidity index (HCT-CI)\u2009\u2265\u20093 21.3% versus 40.8%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001 and Karnofsky performance status (KPS) with KPS\u2009\u2265\u200990 in 78% versus 68.5%, respectively, <jats:italic>p<\/jats:italic>\u2009=\u20090.002. The two patient groups did not differ with respect to gender, cytomegalovirus serostatus, and cell source. Median time from diagnosis to HaploSCT was 5.2 versus 4.9\u00a0months, respectively, <jats:italic>p<\/jats:italic>\u2009=\u20090.005. Fewer sAML patients received myeloablative conditioning 35.1% versus 50.1%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001. Two hundred and eleven sAML and 410 de novo AML patients were included in the matched-pair analysis matching two de novo AML with each sAML. No significant difference was observed in any transplantation outcome parameter between the sAML versus de novo AML groups. Two-year non-relapse mortality and relapse incidence did not differ with HaploSCT for de novo versus sAML; 21.4% versus 21%, hazard ratio (HR)\u2009=\u20090.98, <jats:italic>p<\/jats:italic>\u2009=\u20090.9 and 23.4% versus 20.6%, HR\u2009=\u20090.92, <jats:italic>p<\/jats:italic>\u2009=\u20090.67, respectively. Two-year leukemia-free survival, overall survival, and graft-versus-host disease (GVHD)-free, relapse-free survival were also not different between the de novo AML and sAML groups 55.2% versus 58.4%, HR\u2009=\u20090.95, <jats:italic>p<\/jats:italic>\u2009=\u20090.67; 61.4% versus 66.4%, HR\u2009=\u20090.91, <jats:italic>p<\/jats:italic>\u2009=\u20090.51 and 46.3% versus 48.2%, HR\u2009=\u20090.92, <jats:italic>p<\/jats:italic>\u2009=\u20090.48, respectively. Similarly, the incidence of engraftment as well as acute and chronic GVHD was similar between the 2 cohorts. In conclusion, HaploSCT with PTCy may be able to overcome the bad prognosis of sAML as results are not significantly different to those of HaploSCT in de novo AML.<\/jats:p>","DOI":"10.1186\/s13045-023-01450-4","type":"journal-article","created":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T11:01:43Z","timestamp":1685358103000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP\/EBMT"],"prefix":"10.1186","volume":"16","author":[{"given":"Arnon","family":"Nagler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Labopin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Blaise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Raiola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia Lopez","family":"Corral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Bramanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Sica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yener","family":"Koc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiri","family":"Pavlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Kulagin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Busca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arancha Berm\u00fadez","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Rem\u00e9nyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eolia","family":"Brissot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Bazarbachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Giebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Ciceri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,29]]},"reference":[{"issue":"31","key":"1450_CR1","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1200\/JCO.2014.60.0890","volume":"33","author":"LS Granfeldt Ostgard","year":"2015","unstructured":"Granfeldt Ostgard LS, Medeiros BC, Sengelov H, Norgaard M, Andersen MK, Dufva IH, et al. Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute MSecondary AML is generally associated with poor clinical outcomes compared to de novo AMLyeloid Leukemia: a National Population-Based Cohort Study. J Clin Oncol. 2015;33(31):3641\u20139.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1450_CR2","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/ajh.23908","volume":"90","author":"E Huleg\u00e5rdh","year":"2015","unstructured":"Huleg\u00e5rdh E, Nilsson C, Lazarevic V, Garelius H, Antunovic P, Rangert Derolf \u00c5, et al. Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry. Am J Hematol. 2015;90(3):208\u201314.","journal-title":"Am J Hematol"},{"issue":"8","key":"1450_CR3","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.leukres.2013.04.016","volume":"37","author":"MG Della Porta","year":"2013","unstructured":"Della Porta MG. Prognosis of secondary acute myeloid leukemia. Leuk Res. 2013;37(8):857\u20138.","journal-title":"Leuk Res"},{"issue":"7","key":"1450_CR4","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood-2010-08-301713","volume":"117","author":"S Kayser","year":"2011","unstructured":"Kayser S, D\u00f6hner K, Krauter J, K\u00f6hne C-H, Horst HA, Held G, et al. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood. 2011;117(7):2137\u201345.","journal-title":"Blood"},{"issue":"8","key":"1450_CR5","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11864-015-0355-3","volume":"16","author":"SB Zeichner","year":"2015","unstructured":"Zeichner SB, Arellano ML. Secondary adult acute myeloid leukemia: a review of our evolving understanding of a complex disease process. Curr Treat Options Oncol. 2015;16(8):37.","journal-title":"Curr Treat Options Oncol"},{"issue":"1","key":"1450_CR6","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s11899-021-00608-6","volume":"16","author":"DR Richardson","year":"2021","unstructured":"Richardson DR, Green SD, Foster MC, Zeidner JF. Secondary AML emerging after therapy with hypomethylating agents: outcomes, prognostic factors, and treatment options. Curr Hematol Malig Rep. 2021;16(1):97\u2013111.","journal-title":"Curr Hematol Malig Rep"},{"issue":"19","key":"1450_CR7","doi-asserted-by":"crossref","first-page":"7140","DOI":"10.3390\/ijms21197140","volume":"21","author":"M Bauer","year":"2020","unstructured":"Bauer M, Vaxevanis C, Heimer N, Al-Ali HK, Jaekel N, Bachmann M, et al. Expression, regulation and function of microRNA as important players in the transition of MDS to secondary AML and their cross talk to RNA-binding proteins. Int J Mol Sci. 2020;21(19):7140.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"1450_CR8","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1182\/blood-2009-10-249128","volume":"115","author":"MR Litzow","year":"2010","unstructured":"Litzow MR, Tarima S, Perez WS, Bolwell BJ, Cairo MS, Camitta BM, et al. Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood. 2010;115(9):1850\u20137.","journal-title":"Blood"},{"issue":"7","key":"1450_CR9","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.bbmt.2018.04.008","volume":"24","author":"S Sengsayadeth","year":"2018","unstructured":"Sengsayadeth S, Labopin M, Boumendil A, Finke J, Ganser A, Stelljes M, et al. Transplant outcomes for secondary acute myeloid leukemia: acute leukemia working party of the european society for blood and bone marrow transplantation study. Biol Blood Marrow Transplant. 2018;24(7):1406\u201314.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"1450_CR10","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41408-020-0296-3","volume":"10","author":"A-K Schmaelter","year":"2020","unstructured":"Schmaelter A-K, Labopin M, Soci\u00e9 G, It\u00e4l\u00e4-Remes M, Blaise D, Yakoub-Agha I, et al. Inferior outcome of allogeneic stem cell transplantation for secondary acute myeloid leukemia in first complete remission as compared to de novo acute myeloid leukemia. Blood Cancer J. 2020;10(3):26.","journal-title":"Blood Cancer J"},{"issue":"8","key":"1450_CR11","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.bbmt.2020.04.004","volume":"26","author":"M Kida","year":"2020","unstructured":"Kida M, Usuki K, Uchida N, Fukuda T, Katayama Y, Kondo T, et al. Outcome and risk factors for therapy-related myeloid neoplasms treated with allogeneic stem cell transplantation in Japan. Biol Blood Marrow Transplant. 2020;26(8):1543\u201351.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"1450_CR12","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/j.bbmt.2019.05.038","volume":"25","author":"C Nilsson","year":"2019","unstructured":"Nilsson C, Huleg\u00e5rdh E, Garelius H, M\u00f6llg\u00e5rd L, Brune M, Wahlin A, et al. Secondary acute myeloid leukemia and the role of allogeneic stem cell transplantation in a population-based setting. Biol Blood Marrow Transplant. 2019;25(9):1770\u20138.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1450_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-022-01825-0","author":"A Nagler","year":"2022","unstructured":"Nagler A, Ngoya M, Galimard JE, Labopin M, Kr\u00f6ger N, Soci\u00e9 G, et al. Trends in outcome of transplantation in patients with secondary acute myeloid leukemia: an analysis from the Acute Leukemia Working Party (ALWP) of the EBMT. Bone Marrow Transplant. 2022. https:\/\/doi.org\/10.1038\/s41409-022-01825-0.","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"1450_CR14","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/s41409-022-01693-8","volume":"57","author":"A Nagler","year":"2022","unstructured":"Nagler A, Peczynski C, Dholaria B, Labopin M, Valerius T, Dreger P, et al. Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemia. Bone Marrow Transplant. 2022;57(7):1116\u201323.","journal-title":"Bone Marrow Transplant"},{"issue":"19","key":"1450_CR15","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1182\/blood-2015-01-623991","volume":"125","author":"SR McCurdy","year":"2015","unstructured":"McCurdy SR, Kanakry JA, Showel MM, Tsai HL, Bola\u00f1os-Meade J, Rosner GL, et al. Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. Blood. 2015;125(19):3024\u201331.","journal-title":"Blood"},{"issue":"28","key":"1450_CR16","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1200\/JCO.2014.60.4777","volume":"33","author":"YL Kasamon","year":"2015","unstructured":"Kasamon YL, Bola\u00f1os-Meade J, Prince GT, Tsai HL, McCurdy SR, Kanakry JA, et al. Outcomes of nonmyeloablative HLA-haploidentical blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in older adults. J Clin Oncol. 2015;33(28):3152\u201361.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1450_CR17","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/ajh.25087","volume":"93","author":"Z Li","year":"2018","unstructured":"Li Z, Labopin M, Ciceri F, Blaise D, Tischer J, Ehninger G, et al. Haploidentical transplantation outcomes for secondary acute myeloid leukemia: acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) study. Am J Hematol. 2018;93(6):769\u201377.","journal-title":"Am J Hematol"},{"issue":"12","key":"1450_CR18","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1038\/s41409-019-0582-5","volume":"54","author":"A Ruggeri","year":"2019","unstructured":"Ruggeri A, Labopin M, Savani B, Paviglianiti A, Blaise D, Volt F, et al. Hematopoietic stem cell transplantation with unrelated cord blood or haploidentical donor grafts in adult patients with secondary acute myeloid leukemia, a comparative study from Eurocord and the ALWP EBMT. Bone Marrow Transplant. 2019;54(12):1987\u201394.","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"1450_CR19","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1038\/s41375-019-0686-3","volume":"34","author":"S Yu","year":"2020","unstructured":"Yu S, Huang F, Wang Y, Xu Y, Yang T, Fan Z, et al. Haploidentical transplantation might have superior graft-versus-leukemia effect than HLA-matched sibling transplantation for high-risk acute myeloid leukemia in first complete remission: a prospective multicentre cohort study. Leukemia. 2020;34(5):1433\u201343.","journal-title":"Leukemia"},{"issue":"6","key":"1450_CR20","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.bbmt.2010.08.023","volume":"17","author":"Y Wang","year":"2011","unstructured":"Wang Y, Liu DH, Xu LP, Liu KU, Chen H, Chen YH, et al. Superior graft-versus-leukemia effect associated with transplantation of haploidentical compared with HLA-identical sibling donor grafts for high-risk acute leukemia: an historic comparison. Biol Blood Marrow Transplant. 2011;17(6):821\u201330.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"17","key":"1450_CR21","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood-2016-12-754796","volume":"129","author":"T Yoshizato","year":"2017","unstructured":"Yoshizato T, Nannya Y, Atsuta Y, Shiozawa Y, Iijima-Yamashita Y, Yoshida K, et al. Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation. Blood. 2017;129(17):2347\u201358.","journal-title":"Blood"},{"issue":"24","key":"1450_CR22","doi-asserted-by":"crossref","first-page":"6475","DOI":"10.1158\/1078-0432.CCR-20-3134","volume":"26","author":"A Bazarbachi","year":"2020","unstructured":"Bazarbachi A, Schmid C, Labopin M, Beelen D, Wolfgang Blau I, Potter V, et al. Evaluation of trends and prognosis over time in patients with AML relapsing after allogeneic hematopoietic cell transplant reveals improved survival for young patients in recent years. Clin Cancer Res. 2020;26(24):6475\u201382.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"1450_CR23","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15(12):1628\u201333.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"1450_CR24","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15(6):825\u20138.","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"1450_CR25","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/0002-9343(80)90380-0","volume":"69","author":"HM Shulman","year":"1980","unstructured":"Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69(2):204\u201317.","journal-title":"Am J Med"},{"key":"1450_CR26","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/bmt.2015.305","volume":"51","author":"A Ruggeri","year":"2016","unstructured":"Ruggeri A, Labopin M, Ciceri F, Mohty M, Nagler A. Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission. Bone Marrow Transplant. 2016;51:610\u20131.","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"1450_CR27","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2991\/chi.d.191207.001","volume":"2","author":"AS Kanate","year":"2019","unstructured":"Kanate AS, Nagler A, Savani B. Summary of scientific and statistical methods, study endpoints and definitions for observational and registry-based studies in hematopoietic cell transplantation. Clin Hematol Int. 2019;2(1):2\u20134.","journal-title":"Clin Hematol Int"},{"key":"1450_CR28","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1002\/(SICI)1097-0258(19990630)18:12<1489::AID-SIM140>3.0.CO;2-#","volume":"18","author":"PK Andersen","year":"1999","unstructured":"Andersen PK, Klein JP, Zhang MJ. Testing for center effects in multi-center survival studies: a Monte Carlo comparison of fixed and random effects tests. Stat Med. 1999;18:1489\u2013500.","journal-title":"Stat Med"},{"issue":"19","key":"1450_CR29","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1002\/sim.5753","volume":"32","author":"DF McCaffrey","year":"2013","unstructured":"McCaffrey DF, Griffin BA, Almirall D, Slaughter ME, Ramchand R, Burgette LF. A tutorial on propensity score estimation for multiple treatments using generalized boosted models. Stat Med. 2013;32(19):3388\u2013414.","journal-title":"Stat Med"},{"key":"1450_CR30","unstructured":"A language and environment for statistical computing. https:\/\/www.R-project.org\/. R Core Team: R Foundation for Statistical Computing, Vienna, Austria, 2020."},{"key":"1450_CR31","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1002\/cncr.30704","volume":"123","author":"PC Boddu","year":"2017","unstructured":"Boddu PC, Kantarjian HM, Ravandi F, Garcia-Manero G, Verstovsek S, Jabbour EJ, et al. Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach. Cancer. 2017;123:3050\u201360.","journal-title":"Cancer"},{"key":"1450_CR32","doi-asserted-by":"crossref","first-page":"185","DOI":"10.5045\/br.2013.48.3.185","volume":"48","author":"SH Park","year":"2013","unstructured":"Park SH, Chi H-S, Cho Y-U, Jang S, Park C-J. Evaluation of prognostic factors in patients with therapy-related acute myeloid leukemia. Blood Res. 2013;48:185.","journal-title":"Blood Res"},{"key":"1450_CR33","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1200\/JCO.2001.19.5.1405","volume":"19","author":"DH Christiansen","year":"2001","unstructured":"Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. J Clin Oncol. 2001;19:1405\u201313.","journal-title":"J Clin Oncol"},{"key":"1450_CR34","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3324\/haematol.2017.168716","volume":"103","author":"C Schmid","year":"2018","unstructured":"Schmid C, De Wreede LC, Van Biezen A, Finke J, Ehninger G, Ganser A, et al. Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of B. Haematologica. 2018;103:237\u201345.","journal-title":"Haematologica"},{"issue":"8","key":"1450_CR35","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1182\/blood-2015-04-639831","volume":"126","author":"SO Ciurea","year":"2015","unstructured":"Ciurea SO, Zhang MJ, Bacigalupo AA, Bashey A, Appelbaum FR, Aljitawi OS, et al. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood. 2015;126(8):1033\u201340.","journal-title":"Blood"},{"issue":"6","key":"1450_CR36","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1172\/JCI124218","volume":"129","author":"LP Wachsmuth","year":"2019","unstructured":"Wachsmuth LP, Patterson MT, Eckhaus MA, Venzon DJ, Gress RE, Kanakry CG. Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression. J Clin Investig. 2019;129(6):2357\u201373.","journal-title":"J Clin Investig"},{"issue":"2","key":"1450_CR37","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.bbmt.2019.09.030","volume":"26","author":"LP Wachsmuth","year":"2020","unstructured":"Wachsmuth LP, Patterson MT, Eckhaus MA, Venzon DJ, Kanakry CG. Optimized timing of post-transplantation cyclophosphamide in MHC-haploidentical murine hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2020;26(2):230\u201341.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"1450_CR38","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13045-020-00882-6","volume":"13","author":"J Sanz","year":"2020","unstructured":"Sanz J, Galimard JE, Labopin M, Afanasyev B, Angelucci E, Ciceri F, et al. Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT. J Hematol Oncol. 2020;13(1):46.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"1450_CR39","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1038\/s41423-020-00597-1","volume":"18","author":"H Guo","year":"2021","unstructured":"Guo H, Chang YJ, Hong Y, Xu LP, Wang Y, Zhang XH, Wang M, Chen H, Chen YH, Wang FR, Wei-Han SYQ, Yan CH, Tang FF, Mo XD, Liu KY, Huang XJ. Dynamic immune profiling identifies the stronger graft-versus-leukemia (GVL) effects with haploidentical allografts compared to HLA-matched stem cell transplantation. Cell Mol Immuno. 2021;18(5):1172\u201385.","journal-title":"Cell Mol Immuno"},{"issue":"1","key":"1450_CR40","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s13045-017-0502-3","volume":"10","author":"Y-J Chang","year":"2017","unstructured":"Chang Y-J, Wang Y, Liu Y-R, Xu LP, Zhang XH, Chen H, et al. Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis. J Hematol Oncol. 2017;10(1):134.","journal-title":"J Hematol Oncol"},{"issue":"8","key":"1450_CR41","doi-asserted-by":"crossref","first-page":"haematol.2018.1","DOI":"10.3324\/haematol.2018.189258","volume":"103","author":"D Salvatore","year":"2018","unstructured":"Salvatore D, Labopin M, Ruggeri A, Battipaglia G, Ghavamzadeh A, Ciceri F, et al. Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2018;103(8):haematol.2018.189258.","journal-title":"Haematologica"},{"issue":"19","key":"1450_CR42","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/j.scib.2022.09.004","volume":"67","author":"NC Gorin","year":"2022","unstructured":"Gorin NC, Huang XJ. A vision for the future of allogeneic hematopoietic stem cell transplantation in the next decade. Sci Bull (Beijing). 2022;67(19):1921\u20134.","journal-title":"Sci Bull (Beijing)"},{"issue":"11","key":"1450_CR43","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1182\/blood.2019000487","volume":"134","author":"G Battipaglia","year":"2019","unstructured":"Battipaglia G, Labopin M, Kr\u00f6ger N, Vitek A, Afanasyev B, Hilgendorf I, et al. Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation. Blood. 2019;134(11):892\u20139.","journal-title":"Blood"},{"issue":"7","key":"1450_CR44","first-page":"589","volume":"39","author":"Q Fei","year":"2018","unstructured":"Fei Q, Huang XJ, Liu Y, Xu LP, Zhang XH, Liu KY, Chen H, Chen YY, Wang Y. The clinical analysis of haploidentical stem cell transplantation in myelodysplastic syndrome-associated acute myeloid leukemia. Zhonghua Xue Ye Xue Za Zhi. 2018;39(7):589.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"16","key":"1450_CR45","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/bloodadvances.2018019976","volume":"2","author":"S Sengsayadeth","year":"2018","unstructured":"Sengsayadeth S, Gatwood KS, Boumendil A, Labopin M, Finke J, Ganser A, et al. Conditioning intensity in secondary AML with prior myelodysplastic syndrome\/myeloproliferative disorders: an EBMT ALWP study. Blood Adv. 2018;2(16):2127\u201335.","journal-title":"Blood Adv"},{"key":"1450_CR46","unstructured":"Scott BL, Pasquini MC, Logan BR, Wu J, Devine SM, Porter DL, et al. Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes."},{"issue":"11","key":"1450_CR47","doi-asserted-by":"crossref","first-page":"773.e1","DOI":"10.1016\/j.jtct.2022.08.018","volume":"28","author":"A Nagler","year":"2022","unstructured":"Nagler A, Labopin M, Dholaria B, Ciceri F, Fraccaroli A, Blaise D, et al. Impact of cytogenetic risk on outcomes of non-T-cell-depleted haploidentical hematopoietic cell transplantation in patients with relapsed or refractory acute myeloid leukemia. Transplant Cell Ther. 2022;28(11):773.e1-773.e8.","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"1450_CR48","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1158\/1078-0432.CCR-20-2809","volume":"27","author":"A Nagler","year":"2021","unstructured":"Nagler A, Labopin M, Dholaria B, Angelucci E, Afanasyev B, Cornelissen JJ, et al. Comparison of haploidentical bone marrow versus matched unrelated donor peripheral blood stem cell transplantation with posttransplant cyclophosphamide in patients with acute leukemia. Clin Cancer Res. 2021;27(3):843\u201351.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"1450_CR49","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1002\/cncr.32629","volume":"126","author":"NC Gorin","year":"2020","unstructured":"Gorin NC, Labopin M, Blaise D, de Groot M, Soci\u00e9 G, Bourhis JH, et al. Stem cell transplantation from a haploidentical donor versus a genoidentical sister for adult male patients with acute myelogenous leukemia in first remission: a retrospective study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation. Cancer. 2020;126(5):1004\u201315.","journal-title":"Cancer"},{"key":"1450_CR50","doi-asserted-by":"crossref","first-page":"e481","DOI":"10.1016\/S2352-3026(21)00134-4","volume":"8","author":"JE Lancet","year":"2021","unstructured":"Lancet JE, Uy GL, Newell LF, Lin TL, Ritchie EK, Stuart RK, et al. Cortes JE.CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2021;8:e481\u201391.","journal-title":"Lancet Haematol"}],"updated-by":[{"DOI":"10.1186\/s13045-023-01501-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T00:00:00Z","timestamp":1695945600000}}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-023-01450-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-023-01450-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-023-01450-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T01:43:06Z","timestamp":1700530986000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-023-01450-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,29]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1450"],"URL":"https:\/\/doi.org\/10.1186\/s13045-023-01450-4","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s13045-023-01501-w","asserted-by":"object"}]},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,29]]},"assertion":[{"value":"9 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13045-023-01501-w","URL":"https:\/\/doi.org\/10.1186\/s13045-023-01501-w","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The scientific boards of the ALWP of the EBMT approved this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no relevant conflict of interest and no competing financial interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"58"}}